Expert Video - Which genetic mutations and cytogenetic changes have a less favorable response to MDS treatment?
Rafael Bejar, MD, PhD, of the MDS Center of Excellence at the University of California San Diego, discusses cytogenetic changes such as a deletion or partial deletion of chromosome 7 which are linked to poorer outcomes with myelodysplastic syndromes (MDS). He also discusses how a mutation in the gene TP53 or multiple chromosomal abnormalities indicate less favorable responses to MDS treatment.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.